公开(公告)号：US20240000958A1

公开(公告)日：2024-01-04

申请号：US18252783

申请日：2021-11-12

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Francesca Micoli ,  Roberta Di Benedetto ,  Allan Saul

IPC: A61K47/64 ,  A61K39/09 ,  A61P31/04

CPC classification number: A61K47/646 ,  A61K39/092 ,  A61P31/04 ,  A61K2039/6037

Abstract: The present invention is directed to a polysaccharide conjugate comprising or consisting of a one or more polysaccharide conjugated to a carrier polypeptide, wherein the carrier polypeptide is selected from the group consisting of (a) a Streptococcus pyogenes SpyAD (Spy0269, GAS40), a Streptococcus pyogenes SpyCEP (Spy0416, GAS57), or Streptococcus pyogenes SLO (Spy0167, GAS25); (b) CRM197; or (c) a variant, fragment and/or fusion of (a) or (b), improved conjugation methods, and uses of said conjugates for preventing or treating disease.

公开(公告)号：US20230390381A1

公开(公告)日：2023-12-07

申请号：US18082456

申请日：2022-12-15

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ann-Muriel STEFF ,  Jean-Francois TOUSSAINT ,  Alessandra VITELLI

IPC: A61K39/155 ,  A61K39/235 ,  A61K39/12

CPC classification number: A61K39/155 ,  A61K39/235 ,  A61K39/12 ,  A61K2039/5256

Abstract: This disclosure provides immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent, e.g., co-localized, administration. More specifically, the respiratory pathogen is respiratory syncytial virus (RSV). This disclosure also concerns provides the use of such immunogenic combinations, and methods for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.

公开(公告)号：US20230381106A1

公开(公告)日：2023-11-30

申请号：US18231693

申请日：2023-08-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew GEALL

IPC: A61K9/127 ,  A61K31/7088 ,  A61K39/00 ,  A61K39/12 ,  C12N15/86

CPC classification number: A61K9/127 ,  A61K9/1272 ,  A61K31/7088 ,  A61K39/00 ,  A61K39/12 ,  C12N15/86 ,  C12N2770/36134 ,  A61K39/39

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.

公开(公告)号：US20230381105A1

公开(公告)日：2023-11-30

申请号：US18231692

申请日：2023-08-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew GEALL

IPC: A61K9/127 ,  A61K39/12 ,  C12N15/86 ,  A61K31/7088 ,  A61K39/00

CPC classification number: A61K9/127 ,  A61K9/1272 ,  A61K39/12 ,  C12N15/86 ,  A61K31/7088 ,  A61K39/00 ,  A61K2039/55555 ,  C12N2760/18534 ,  A61K39/39

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.

公开(公告)号：US11827694B2

公开(公告)日：2023-11-28

申请号：US18173006

申请日：2023-02-22

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt Swanson ,  Philip R. Dormitzer

IPC: C07K16/10 ,  A61K39/155 ,  A61K39/12 ,  C07K14/005 ,  A61K39/00

CPC classification number: C07K16/1027 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  A61K39/00 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/50 ,  C07K2319/73 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2770/36143

Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.

公开(公告)号：US11813323B2

公开(公告)日：2023-11-14

申请号：US17849392

申请日：2022-06-24

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Philip Dormitzer

IPC: A61K39/155 ,  A61K39/12 ,  A61P31/14 ,  A61K39/00

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61P31/14 ,  A61K2039/545 ,  A61K2039/55 ,  C12N2760/18634

Abstract: The invention relates to an immunization regimen whereby an infant is protected against respiratory syncytial virus (RSV) through administration of a first anti-RSV immune response inducing composition to his or her mother during pregnancy, followed by administration of a second anti-RSV immune response inducing composition to the infant after birth.

公开(公告)号：US20230357371A1

公开(公告)日：2023-11-09

申请号：US18323192

申请日：2023-05-24

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Philip R. DORMITZER

IPC: C07K16/10 ,  A61K39/155 ,  A61K39/12 ,  C07K14/005

CPC classification number: C07K16/1027 ,  A61K39/155 ,  A61K39/12 ,  C07K14/005 ,  A61K2039/5252

Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.

公开(公告)号：US20230321132A1

公开(公告)日：2023-10-12

申请号：US18333591

申请日：2023-06-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew GEALL ,  Katrin RAMSAUER ,  Gillis OTTEN ,  Christian Walter MANDL

IPC: A61K31/7088 ,  A61K39/00 ,  A61K39/12

CPC classification number: A61K31/7088 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/55555 ,  C12N2760/18534 ,  A61K2039/53 ,  C12N2760/18522 ,  C12N2770/36143

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.

公开(公告)号：US11773395B1

公开(公告)日：2023-10-03

申请号：US18065243

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: C12N15/117 ,  C12N15/86 ,  A61K39/155 ,  A61K39/39 ,  A61K39/12 ,  A61P31/12 ,  A61P37/04 ,  A61K48/00 ,  A61K39/00

CPC classification number: C12N15/117 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  A61K48/0041 ,  A61K48/0083 ,  A61P31/12 ,  A61P37/04 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2820/60

Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.

公开(公告)号：US11773139B2

公开(公告)日：2023-10-03

申请号：US16770963

申请日：2018-12-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefania Capone ,  Antonella Folgori ,  Armin Lahm ,  Benjamin Wizel

IPC: C07K14/005 ,  A61K39/245 ,  C12N7/00 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K39/245 ,  C12N7/00 ,  A61K2039/70 ,  C12N2710/16222 ,  C12N2710/16234 ,  C12N2710/16271

Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.